|
1）Paczesny S, Krijanovski OI, Braun TM, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2009; 113(2): 273-8
|
|
|
|
2）Harris AC, Ferrara JL, Braun TM, et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood. 2012; 119(12): 2960-3
|
|
|
|
|
3）Choi SW, Kitko CL, Braun T, et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood. 2008; 112(4): 1539-42
|
|
|
|
|
|
4）Suthanthiran M, Schwartz JE, Ding R, et al. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med. 2013; 369(1): 20-31
|
|
|
|
|
|
5）Paczesny S. Discovery and validation of graft-versus-host disease biomarkers. Blood. 2013; 121(4): 585-94
|
|
|
|
|
|
6）Paczesny S, Braun TM, Levine JE, et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med. 2010; 2(13): 13ra2
|
|
|
|
|
|
7）Ferrara JL, Harris AC, Greenson JK, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011; 118(25): 6702-8
|
|
|
|
|
|
8）Takashima S, Kadowaki M, Aoyama K, et al. The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cells. J Exp Med. 2011; 208(2): 285-94
|
|
|
|
|
|
9）Eriguchi Y, Takashima S, Oka H, et al. Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of alpha-defensins. Blood. 2012; 120(1): 223-31
|
|
|
|
|
|
10）Eriguchi Y, Uryu H, Nakamura K, et al. Reciprocal expression of enteric antimicrobial proteins in intestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2013; 19(10): 1525-9
|
|
|
|
|
|
11）Herrera AF, Soriano G, Bellizzi AM, et al. Cord colitis syndrome in cord-blood stem-cell transplantation. N Engl J Med. 2011; 365(9): 815-24
|
|
|
|
|
|
12）Shimoji S, Kato K, Eriguchi Y, et al. Evaluating the association between histological manifestations of cord colitis syndrome with GVHD. Bone Marrow Transplant. 2013; 48(9): 1249-52
|
|
|
|
|
|
13）August KJ, Chiang KY, Bostick RM, et al. Biomarkers of immune activation to screen for severe, acute GVHD. Bone Marrow Transplant. 2011; 46(4): 601-4
|
|
|
|
|
|
14）Levine JE, Logan BR, Wu J, et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood. 2012; 119(16): 3854-60
|
|
|
|
|
|
15）Vander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease. N Engl J Med. 2013; 369: 529-39
|
|
|
|
|